Abstract
Pediatric uveitis embraces a group of inflammatory diseases affecting the vascular layer of the eye. Among the broad spectrum of possible etiologies, juvenile idiopathic arthritis stands for the most common cause of anterior chronic uveitis in Western countries. Despite being considered a rare disease, non-infectious chronic uveitis is a serious and disabling sight-threatening condition accounting for up to 10 % of pathologies leading to blindness. Visual complications arise as a consequence of persistent or recurrent ocular inflammation, but also as result of chronic steroid treatment. Targeted antimicrobial treatment is necessary for infectious uveitis. On the other hand, non-infectious uveitis is managed trough a “step-by-step” approach, in order to control local inflammation, achieve a corticosteroid-sparing effect and reduce the risk of visual complications. Therapeutic options include corticosteroids, conventional immune-modulatory therapy and tumor necrosis factor α [TNF-α] antagonists. Preliminary evidence suggests a possible role of non anti-TNF-α modifier immunosuppressive treatment for refractory cases, accounting for about 25 % of total patients. Given the high cost and the lack of long-term safety data, the experience with these agents is still limited to few cases managed in highly specialized centers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Miserocchi E, Fogliato G, Modorati G, Bandello F (2013) Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol 23(5):705–717
Petty RE, Rosenbaum JT (2011) Uveitis in juvenile idiopatic arthritis. In: Cassidy J (ed) Textbook of pediatric rheumatology 6th edn. Saunders, Philadelphia, pp 305–314
Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED (2007) Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 56:647–657
Rosenberg K, Feuer WJ, Davis JL (2004) Ocular complications of pediatric uveitis. Ophthalmology 111:2299–2306
Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R (2010) Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 9:674–683
Cantarini L, Simonini G, Frediani B, Pagnini I, Galeazzi M, Cimaz R (2012) Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Investig Drugs 21:1–6
Rabinovich CE (2011) Treatment of juvenile idiopathic arthritis-associated uveitis: challenges and update. Curr Opin Rheumatol 23:432–436
Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ (2012) Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology 52:825–831
Simonini G, Taddio A, Cattalini M, Caputo R, libero C, Naviglio S, Bresci C, Lorusso M, Lepore L, Cimaz R (2011) Prevention off flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63:612–618
Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F, Pagnini I, Lepore L, Cimaz R (2013) Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 15:11–16
Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT (2014) Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 66:1073–1084
Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis-a case report. J Rheumatol 35:1897–1898
Elhai M, Deslandre CJ, Kahan A (2011) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res 63:307–308
Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 249:297–300
Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62:821–825
Tappeiner C, Miserocchi E, Bodaghi B, Kotaniemi K, Mackensen F, Gerloni V et al (2015) Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 42:706–711
Marrani E, Paganelli V, de Libero C, Cimaz R, Simonini G (2015) Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series. Graefes Arch Clin Exp Ophthalmol 253:1813–1816
Simonini G, Cimaz R, Jones GT, Macfarlane GJ (2015) Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: the current evidence from a systematic review. Semin Arthritis Rheum 45:238–250
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Brambilla, A., Cimaz, R., Simonini, G. (2016). Childhood Uveitis. In: Dammacco, F., Ribatti, D., Vacca, A. (eds) Systemic Vasculitides: Current Status and Perspectives. Springer, Cham. https://doi.org/10.1007/978-3-319-40136-2_24
Download citation
DOI: https://doi.org/10.1007/978-3-319-40136-2_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40134-8
Online ISBN: 978-3-319-40136-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)